Luis Teixeira

Université Paris Cité

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (11)

Daniel Rea

Professor of Medical Oncology

University of Birmingham

UNITED KINGDOM

View details

Iain Macpherson

Professor of Breast Oncology

UNITED KINGDOM

View details

Judith Balmaña

Head

Hospital Universitari Vall d'Hebron

SPAIN

View details

Hope Rugo

Professor of Medicine

UNITED STATES

View details

Andrea Eisen

McMaster University

CANADA

View details

Hervé Bischoff

Institut de Cancérologie Strasbourg

FRANCE

View details

seamus o'reilly

prof

Cork University Hospital

IRELAND

View details

Virginie Westeel

Université de Franche-Comté

FRANCE

View details

Anne-Sophie HAMY

Institut Curie

FRANCE

View details

Isabelle Demeestere

Université libre de Bruxelles

BELGIUM

View details

Rafal Tarnawski

Head of Department

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Luis Teixeira

Research Interests

Explore related searches

Contact this professor

Articles (20)

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

A Life course approach to investigate breast cancer and migration in the greater Paris area: the SENOVIE study protocol

Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

Dynamic Projection of Medication Nonpersistence and Nonadherence Among Patients With Early Breast Cancer.

Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.

Access to oncology care in Mali: a qualitative study on breast cancer.

Diagnostic et prise en charge de la pneumopathie interstitielle diffuse induite par les anticorps conjugués dans le cancer du sein : avis d’expert

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Ten-year outcomes of hypofractionated postmastectomy radiation therapy of 26 Gy in 6 fractions

Collaborators (11)

Daniel Rea

Iain Macpherson

Judith Balmaña

Hope Rugo

Andrea Eisen

Hervé Bischoff

seamus o'reilly

Virginie Westeel

Anne-Sophie HAMY

Isabelle Demeestere

Rafal Tarnawski

Make your next move.